U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07050433) titled 'Correlate Biomarkers for the SYNERGY- 201 Study' on June 04.
Brief Summary: This study is a companion to the SYNERGY-201 clinical trial (NCT06228053), which investigates SX-682 and enzalutamide in individuals with prostate cancer. Individuals must be participating in SYNERGY-201 in order to participate in this study. The purpose of this companion study is to learn more about biomarkers, particularly a biomarker called CXCR2, and investigate if CXCR2 can predict who will receive benefit from the SYNERGY-201 drug combination. This study will also investigate how CXCR2 and other biomarkers change over time when participants receive the ...